Safety, PK, and PD of VX-993 in Healthy Adults

Phase 1, randomised, double-blind trial of VX-993 in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses. Started Dec 2022; status: completed.